Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04560738 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04560738 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 8 participants.
The verdict
NCT04560738, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a single-center, open-label study to be conducted in healthy adult male participants. This study is designed to characterize the biotransformation and excretion of \[14C\]-CC-92480 and to evaluate the safety and tolerability of \[14C\]-CC-92480 following a single oral dose of \[14C\]-CC-92480.
Interventions
- DRUG [14C]-CC-92480
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2021-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04560738
The ClinicalTrials.gov registry entry for NCT04560738 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-CC-92480 is the first listed.
NCT04560738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04560738 about?
NCT04560738 is a clinical study titled "A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants". This is a single-center, open-label study to be conducted in healthy adult male participants. This study is designed to characterize the biotransformation and excretion of \[14C\]-CC-92480 and to evaluate the safety and tolerability of \[14C\]-CC-92480 following a single oral dose of \[14C\]-CC-9248...
What is the current status of trial NCT04560738?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-10-15. Estimated completion is 2021-05-13.
What interventions are being tested in trial NCT04560738?
The interventions under investigation include: [14C]-CC-92480 (DRUG).
Who is sponsoring clinical trial NCT04560738?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.